Incredible strong data presented today at #ESMO2026. Why is there so little discussion on X? Much more impactful and practice changing than the $MRNA melanoma data presented today as well…
Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://t.co/9dEqH6apj2
@myESMO
@JacobPlieth Amgen calls this construct a half-life extended (HLE) BITE, compared to the first generation of Fc-less BITE, which they call “canonical BITEs”